16-FEB-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3903 330 195 94 32 7 02/06/2019 472 182
Screened at PD     1416 169 112 56 19 4      
Pre-Screened prior to PD     2467 141 72 31 11 3      
Treatment-naive     20 20 11 7 2 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     524 26 15 6 3 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2093 339 143 71 20 5      
Screened at PD     1186 194 110 56 17 4      
Pre-Screened prior to PD     831 121 21 7 1 0      
Treatment-naive     20 20 11 7 2 1      
After PD on a Lung_MAP Sub-Study     56 4 1 1 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     298 298 121 58 18 4      
S1900G     34 7 3 2 0 0      
S1900J     15 6 3 1 0 0      
S1900K     36 28 16 10 2 1      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     587 92 67 37 15 4      
Initial sub-study registrations     575 92 67 37 15 4      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 62 62 51 27 11 2 05/22/2025 354 114
Docetaxel plus Ramucirumab Y   31 31 25 12 5 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   31 31 26 15 6 2      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 24 7 3 2 0 0 05/05/2023 342 109
Capmatinib + Osimertinib + Ramucirumab Y   14 6 3 2 0 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 2 1 0 0 0 11/19/2024 242 79
Amivantamab Hyaluronidase Y   3 2 1 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 24 21 12 8 4 2 08/08/2024 270 89
Tepotinib + Ramucirumab Y   16 14 8 6 3 2      
Tepotinib Y   8 7 4 2 1 0